About Fatty acyl-CoA reductase 2
Fatty acyl-CoA reductase 2 (FAR2) is a protein
from Homo sapiens identified by UniProt accession
Q96K12, 515 residues long.
MolForge cross-references it against 0 known binders and
117 disease associations.
Target properties
| Protein name | Fatty acyl-CoA reductase 2 |
| UniProt accession | Q96K12 |
| Gene | FAR2 |
| Organism | Homo sapiens |
| Length | 515 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (117)
Diseases linked to this target (Open Targets).
- platelet count · score 0.42
- mean platelet volume · score 0.40
- hair shape measurement · score 0.37
- platelet component distribution width · score 0.36
- breast carcinoma · score 0.34
- balding measurement · score 0.33
- androgenetic alopecia · score 0.29
- heel bone mineral density · score 0.28
- alopecia · score 0.27
- platelet-to-lymphocyte ratio · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96K12-F1 | alphafold | PREDICTED | 94.14 | — |
Amino-acid sequence (515 residues)
MSTIAAFYGG KSILITGATG FLGKVLMEKL FRTSPDLKVI YILVRPKAGQ TLQQRVFQIL DSKLFEKVKE VCPNVHEKIR AIYADLNQND FAISKEDMQE LLSCTNIIFH CAATVRFDDT LRHAVQLNVT ATRQLLLMAS QMPKLEAFIH ISTAYSNCNL KHIDEVIYPC PVEPKKIIDS LEWLDDAIID EITPKLIRDW PNIYTYTKAL GEMVVQQESR NLNIAIIRPS IVGATWQEPF PGWVDNINGP NGIIIATGKG FLRAIKATPM AVADVIPVDT VVNLMLAVGW YTAVHRPKST LVYHITSGNM NPCNWHKMGV QVLATFEKIP FERPFRRPNA NFTSNSFTSQ YWNAVSHRAP AIIYDCYLRL TGRKPRMTKL MNRLLRTVSM LEYFINRSWE WSTYNTEMLM SELSPEDQRV FNFDVRQLNW LEYIENYVLG VKKYLLKEDM AGIPKAKQRL KRLRNIHYLF NTALFLIAWR LLIARSQMAR NVWFFIVSFC YKFLSYFRAS STLKV
Explore Fatty acyl-CoA reductase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets